The purpose of this study is to test whether regulatory T-cell reduction is possible and safe in myeloma subjects undergoing autologous stem cell transplantation (ASCT).

SparkCures ID	257
Trial Phase	Pilot Trial
Enrollment	30 Patients
Treatments	Autologous Stem Cell Transplant Basiliximab Melphalan Plerixafor
Trial Sponsors	University of Chicago Medicine
NCT Identifier	NCT01526096

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

Symptomatic multiple myeloma of any subtype in any disease stage, providing that patient does not have smoldering myeloma.
Patient must otherwise be a candidate for ASCT as determined by treating physician.
No current CNS Myeloma at time of enrollment.
Life expectancy greater than 12 weeks.
Age greater than or equal to 21 and less than or equal to 70 years old.
EGOG performance status less than or equal to 2.
No cardiac, pulmonary, hepatic, or renal contraindications for high dose chemotherapy.
HIV Negative.
No active Hepatitis B or C.
Patients must be able to provide written informed, consent.

Exclusion Criteria:

Pregnant or nursing women. Women of child-bearing age must be tested for pregnancy.
Use of systemic immunosuppressive medications, including corticosteroids, tacrolimus, mycophenolate mofetil, sirolimus or cyclosporine A.
Psychiatric illness which may make compliance to the clinical protocol unmanageable or which may compromise the ability of the patient to give informed consent.
Active autoimmune disease including but not limited to: rheumatoid arthritis inflammatory bowel disease, celiac disease, systemic lupus erythematosis, scleroderma or multiple sclerosis.

Stem Cell Transplantation for Patients With Multiple Myeloma

Overview

Am I Eligible?

US Trial Locations